Trial
NCT07340853
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
Phase ISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Thomas Martin, MD
Collaborators
—
Condition
Multiple Myeloma
Intervention
Leukapheresis
Why stopped
Safety Review
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-11